175358-01-7

Basic information

• Product Name: 6-Chloro-3-aminopyridine-2-carboxamide
• Synonyms: 6-Chloro-3-aminopyridine-2-carboxamide;3-amino-6-chloropicolinamide;3-aMino-6-chloropyridine-2-carboxaMide;3-AMino-6-chloro-pyridine-2-carboxylic acid aMide
• CAS NO: 175358-01-7
• Molecular Formula: C₆H₆ClN₃O
• Molecular Weight: 171.59
• EINECS: 1312995-182-4
• Product Categories: Pyridines
• Mol File: 175358-01-7.mol
• Article Data: 19

Chemical Properties

• Boiling Point: 349.303 °C at 760 mmHg
• Flash Point: 165.053 °C
• Appearance: /
• Density: 1.484 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.655
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 14.26±0.50(Predicted)
• CAS DataBase Reference: 6-Chloro-3-aminopyridine-2-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Chloro-3-aminopyridine-2-carboxamide(175358-01-7)
• EPA Substance Registry System: 6-Chloro-3-aminopyridine-2-carboxamide(175358-01-7)

Safety Data

• Hazardous Substances Data: 175358-01-7(Hazardous Substances Data)

Usage

General Description

6-Chloro-3-aminopyridine-2-carboxamide is a chemical compound with the molecular formula C6H6ClN3O. It is a derivative of pyridine and amide, containing a chlorine atom, an amino group, and a carboxamide group. 6-Chloro-3-aminopyridine-2-carboxamide is used in the pharmaceutical industry as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. It is also used in the production of organic materials and as a building block for the development of potentially bioactive molecules. 6-Chloro-3-aminopyridine-2-carboxamide is commonly utilized in research and drug development due to its versatile reactivity and potential pharmacological properties.

InChI:InChI=1/C6H6ClN3O/c7-4-2-1-3(8)5(10-4)6(9)11/h1-2H,8H2,(H2,9,11)

Upstream product

• 2402-78-0 2,6-dichloropyridine 
• 95095-84-4 3-amino-6-chloro-pyridine-2-carbonitrile 
• 16013-85-7 2,6-dicholoro-3-nitropyridine 
• 93683-65-9 6-chloro-3-nitropicolinonitrile 
• 171178-21-5 6-chloro-3-nitropyridine-2-carboxamide 

Downstream Products

• 917758-83-9 3-amino-6-(4-fluorophenyl)pyridine-2-carboxamide 
• 866807-27-4 3-amino-6-chloro-pyridine-2-carboxylic acid 
• 1400668-23-6 6-chloro-N-(4-(trifluoromethoxy)phenyl)pyrido[3,2-d]pyrimidin-4-amine 
• 1367359-28-1 (S)-6-(4-bromo-2-fluorophenoxy)-3-((1-isopropylpiperidin-3-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4(3H)-one 
• 1367359-25-8 6-(4-chloro-2-fluorophenoxy)-3-((S)-1-isopropylpiperidin-3-ylmethyl)-2-methyl-3H-pyrido[3,2-d]pyrimidin-4-one 
• 1367359-24-7 6-(4-fluorophenoxy)-3-((S)-1-isopropylpiperidin-3-ylmethyl)-2-methyl-3H-pyrido[3,2-d]pyrimidin-4-one 
• 1367359-31-6 C₂₉H₃₂N₄O₂ 
• 1203653-35-3 (R)-N₂-(1-(4-(1H-1,2,4-triazol-1-yl)phenyl)ethyl)-6-(4-methoxy-3-(methylsulfonyl)phenyl)-N₄-(2,2,2-trifluoroethyl)pyrido[3,2-d]pyrimidine-2,4-diamine 
• 1318780-21-0 N-(4-(1H-1,2,4-triazol-1-yl)benzyl)-6-chloro-4-(1-methylcyclopropoxy)pyrido[3,2-d]pyrimidin-2-amine 
• 1203652-46-3 (R)-N₂-(1-(4-(1H-1,2,4-triazol-1-yl)phenyl)ethyl)-6-(3-(methylsulfonyl)phenyl)-N₄-(1-(trifluoromethyl)cyclopropyl)pyrido[3,2-d]pyrimidine-2,4-diamine 
• 1318780-19-6 (R)-N₂-(1-(4-(1H-1,2,4-triazol-1-yl)phenyl)ethyl)-6-chloro-N₄-(1-(trifluoromethyl)cyclopropyl)pyrido[3,2-d]pyrimidine-2,4-diamine 
• 1318780-18-5 (R)-N₂-(1-(4-(1H-1,2,4-triazol-1-yl)phenyl)ethyl)-6-chloro-N₄-(2,2,2-trifluoroethyl)pyrido[3,2-d]pyrimidine-2,4-diamine 
• 1318780-10-7 3-chloro-5-((6-(4-fluorophenyl)-4-(1-(trifluoromethyl)cyclopropylamino)pyrido[3,2-d]pyrimidin-2-ylamino)methyl)benzenesulfonamide trifluoroacetic acid salt 

Relevant articles and documents

Fragment-based drug discovery of potent and selective MKK3/6 inhibitors

The MAPK signaling cascade, comprised of several linear and intersecting pathways, propagates signaling into the nucleus resulting in cytokine and chemokine release. The Map Kinase Kinase isoforms 3 and 6 (MKK3 and MKK6) are responsible for the phosphorylation and activation of p38, and are hypothesized to play a key role in regulating this pathway without the redundancy seen in downstream effectors. Using FBDD, we have discovered efficient and selective inhibitors of MKK3 and MKK6 that can serve as tool molecules to help further understand the role of these kinases in MAPK signaling, and the potential impact of inhibiting kinases upstream of p38.

Optimization of 4,6-Disubstituted Pyrido[3,2-d]pyrimidines as Dual MNK/PIM Inhibitors to Inhibit Leukemia Cell Growth

Mitogen-activated protein kinase-interacting kinases (MNKs) and provirus integration in maloney murine leukemia virus kinases (PIMs) are downstream enzymes of cell proliferation signaling pathways associated with the resistance of tyrosine kinase inhibitors. MNKs and PIMs have complementary effects to regulate cap-dependent translation of oncoproteins. Dual inhibitors of MNKs and PIMs have not been developed. We developed a novel 4,6-disubstituted pyrido[3,2-d]pyrimidine compound 21o with selective inhibition of MNKs and PIMs. The IC50’s of 21o to inhibit MNK1 and MNK2 are 1 and 7 nM and those to inhibit PIM1, PIM2, and PIM3 are 43, 232, and 774 nM, respectively. 21o inhibits the growth of myeloid leukemia K562 and MOLM-13 cells with GI50’s of 2.1 and 1.2 μM, respectively. 21o decreases the levels ofp-eIF4E andp-4EBP1, the downstream products of MNKs and PIMs, as well as cap-dependent proteins c-myc, cyclin D1, and Mcl-1. 21o inhibits the growth of MOLM-13 cell xenografts without causing evident toxicity. 21o represents an innovative dual MNK/PIM inhibitor with a good pharmacokinetic profile.

4, 6-disubstituted pyridine [3, 2-d] pyrimidine compound as well as preparation and application thereof

The invention belongs to the technical field of medicines. The invention relates to the field of pharmaceutical chemistry, in particular to a 4, 6-disubstituted pyridine [3, 2-d] pyrimidine compound and pharmaceutically acceptable salt thereof, a preparation method of the compound, a pharmaceutical composition taking the compound as an active ingredient, and application of the compound in preparation of an MNK inhibitor and drugs for treating and/or preventing various cancers and/or metabolic diseases. The present invention relates to compounds represented by formulas I, II, III or IV, and pharmaceutically acceptable salts, hydrates, solvates and metabolites thereof, wherein the variables are described in the claims and the description.